Genetically modified cellular vaccines against human papillomavirus type 16 (HPV16)-associated tumors: Adjuvant treatment of minimal residual disease after surgery/chemotherapy

Journal of B.U.ON.

Volumn 14, Issue SUPPL.1, 2009, Pages

  Bubenik, J ^a   Simova, J ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

Chemotherapy; HPV16; Residual disease; Surgery; Vaccines

Indexed keywords

DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; INTERLEUKIN 12; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN E6; PROTEIN E7; TUMOR VACCINE;

ADJUVANT CHEMOTHERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER SURGERY; CELLULAR IMMUNITY; CONFERENCE PAPER; CYTOKINE PRODUCTION; GENETIC ENGINEERING; GENETIC TRANSFECTION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMORAL IMMUNITY; KIDNEY CARCINOMA; LUNG CANCER; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MELANOMA; MINIMAL RESIDUAL DISEASE; NONHUMAN; OVARY CANCER; REGULATORY T LYMPHOCYTE; UTERINE CERVIX CANCER;

ANIMALS; CANCER VACCINES; HUMAN PAPILLOMAVIRUS 16; HUMANS; MALE; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM, RESIDUAL; PAPILLOMAVIRUS INFECTIONS; T-LYMPHOCYTES, REGULATORY;

EID: 70350065512     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (54)

1. Yu JS, Wei MX, Chiocca EA, Martuza RL, Tepper RI. Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res 1993; 53: 3125-3128.
2. Bowman L, Grossmann M, Rill D et al. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther 1998; 9: 1303-1311. (Pubitemid 28312895)
3. Bowman L, Grossmann M, Rill D et al. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 1998; 92: 1941-1949. (Pubitemid 28446683)
4. Pizza G, De Vinci C, Lo Conte G et al. Allogeneic gene-modified tumour cells in metastatic kidney cancer. Report II. Folia Biol (Praha) 2004; 50: 175-183.
5. Russell HV, Strother D, Mei Z et al. A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. J Immunother 2008; 31: 812-819.
6. Bubenik J. Cytokine gene-modified vaccines in the therapy of cancer. Pharmacol Ther (Review) 1996; 69: 1-14. (Pubitemid 26061027)
7. Kübler H, Vieweg J. Vaccines in renal cell carcinoma (Review). Semin Oncol 2006; 33: 614-624.
8. Van Poppel H, Joniau S, Van Gool SW. Vaccine Therapy in Patients with Renal Cell Carcinoma. Eur Urol 2009; in press.
9. Dilloo D, Bacon K, Holden W et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med 1996; 2: 1090-1095. (Pubitemid 26338627)
10. Frankenberger B, Regn S, Geiger C et al. Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells. World J Urol 2005; 23: 166-174. (Pubitemid 41136037)
11. Hege KM, Jooss K, Pardoll D. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men (Review). Int Rev Immunol 2006; 25: 321-352. (Pubitemid 44972270)
12. Bubenik J, Simova J, Hajkova R et al. Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16. Int J Oncol 1999; 14: 593-597.
13. Bubenik J. Therapeutic vaccines against HPV16-associated tumors. Minireview. Neoplasma 2002; 49: 285-289. (Pubitemid 35434589)
14. Bubenik J. Genetically modified cellular vaccines for therapy of human papilloma virus type 16 (HPV 16)-associated tumours (Review). Curr Cancer Drug Targets 2008; 8: 180-186. (Pubitemid 351666855)
15. Lin KY, Guarnieri FG, Staveley-O'Carroll KF et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56: 21-26.
16. Smahel M, Sobotkova E, Bubenik J et al. Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16. Br J Cancer 2001; 84: 374-380.
17. Smahel M, Sima P, Ludvikova V, Marinov I, Pokorna D, Vonka V Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class 1 molecules. Vaccine 2003; 21: 1125-1136. (Pubitemid 36142051)
18. Cheng WF, Hung CF, Lin KY et al. CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination. Gene Ther 2003; 10: 1311-1320.
19. Indrova M, Bubenik J, Mikyskova R et al. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines. Int J Oncol 2003; 22: 691-695.
20. Mikyskova R, Indrova M, Simova J et al. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GMCSF. Int J Oncol 2004; 24: 161-167.
21. Lassaro MO, Diniz MO, Reyes-Sandoval A, Ertl HC, Ferreira LC. Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1. Microbes Infect 2005; 7: 1541-1550.
22. Sobotkova E, Duskova M, Eckschlager T, Vonka V. Efficacy of reovirus therapy combined with cyclophosphamide and gene-modified cell vaccines on tumors induced in mice by HPV16-transformed cells. Int J Oncol 2008; 33: 421-426.
23. Lakatosova-Andelova M, Jinoch P, Duskova M, Marinov I, Vonka V. Live cell vaccines expressing B7.1, monocyte chemoattractant protein 1 and granulocyte-macrophage colony stimulation factor derived from mouse HPV16-transformed cells. Int J Oncol 2008; 32: 265-271. (Pubitemid 351176086)
24. Indrova M, Bubenik J, Simova J et al. Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A. Oncol Rep 2001; 8: 1371-1374. (Pubitemid 33758750)
25. Bubenik J, Mikyskova R, Vonka V et al. Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16. Vaccine 2003; 21: 891-896. (Pubitemid 36126423)
26. Indrova M, Bieblova J, Jandlova T, Vonka V, Pajtasz-Piasecka E, Reinis M. Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours. Int J Oncol 2006; 28: 253-259.
27. Ossevoort MA, Feltkamp MC, van Veen KJ, Melief CJ, Kast WM. Dendritic cells as carriers for a cytotoxic T lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother Emphasis Tumor Immunol 1995; 18: 86-94.
28. Wang TL, Ling M, Shih IM et al. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther 2000; 7: 726-733. (Pubitemid 30255753)
29. Mackova J, Stasikova J, Kutinova L et al. Prime/boost immunotherapy of HPV16-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara. Cancer Immunol Immunother 2006; 55: 39-46. (Pubitemid 41783291)
30. Bellone S, Pecorelli S, Cannon MJ, Santin AD. Advances in dendritic-cell-based therapeutic vaccines for cervical cancer (Review). Expert Rev Anticancer Ther 2007; 7: 1473-1486. (Pubitemid 351835155)
31. Dell K, Klein C, Gissmann L. Comparison of DNA- and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type 16 associated oncoprotein E7. Antivir Ther 2008; 13: 495-509. (Pubitemid 352016712)
32. Nonn M, Schinz M, Zumbach K et al. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7. J Cancer Res Clin Oncol 2003; 129: 511-520. (Pubitemid 37211192)
33. Mackova J, Kutinova L, Hainz P et al. Adjuvant effect of dendritic cells transduced with recombinant vaccinia virus expressing HPV 16-E7 is inhibited by co-expression of IL-12. Int J Oncol 2004; 24: 1581-1588.
34. Bubenik J. Human papillomavirus (HPV) and HPV-associated tumour vaccines. Folia Biol (Praha) 2006; 52: 45-46. (Pubitemid 44177821)
35. Indrova M, Bubenik J, Mikyskova R et al. Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin. Int J Oncol 2002; 20: 643-646.
36. Simova J, Bieblova J, Jandlova T, Bubenik J. Immunotherapy of HPV 16-associated tumours with tumour cell line/dendritic cell line (TC-1/DC2.4) hybrid vaccines. Folia Biol (Praha) 2003; 49: 203-206. (Pubitemid 37508703)
37. Reinis M, Indrova M, Mendoza L et al. HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines. Int J Oncol 2004; 25: 1165-1170.
38. Ferrara A, Nonn M, Sehr P et al. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol 2003; 129: 521-530. (Pubitemid 37211193)
39. Vlk V, Rössner P, Indrová M, Bubenik J, Sobota V. Interleukin-2 gene therapy of surgical minimal residual tumour disease. Int J Cancer 1998; 76: 115-119. (Pubitemid 28164577)
40. Simova J, Reinis M, Sobota V, Capkova J, Bubenik J, Jandlova T. Irradiation of genetically modified plasmacytoma vaccines results in upregulation of CD80 molecule expression, IL-2 production and higher therapeutic efficacy of the vaccines. Folia Biol (Praha) 2000; 46: 11-15.
41. Hajkova R, Indrova M, Jandlova T, Bubenik J, Reinis M. Interleukin 2 gene therapy of surgical minimal residual tumour disease: characterization of cytolytic effector cells from tumour progressors and regressors. Folia Biol (Praha) 1999; 45: 227-231. (Pubitemid 29495625)
42. Bubenik J, Simova J. Minimal residual disease as the target for immunotherapy and gene therapy of cancer (Review). Oncol Rep 2005; 14: 1377-1380.
43. Mikyskova R, Bubenik J, Mendoza L et al. Local cytokine treatment of HPV16-associated tumours results in inhibition of their lung metastases. Clin Exp Metastasis 2000; 18: 581-587. (Pubitemid 32964320)
44. Indrova M, Bieblova J, Bubenik J, Reinis M. IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours: induction of immune responses, cytokine production and kinetics of immune cell subsets. Int J Oncol 2008; 32: 499-507. (Pubitemid 351188317)
45. Indrova M, Bieblova J, Rossowska J et al. HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy. Int J Oncol 2009; 34: 173-179.
46. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164.
47. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-336.
48. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061. (Pubitemid 36222930)
49. Stephens GL, McHugh RS, Whitters MJ et al. Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol 2004; 173: 5008-5020.
50. Zou W. Regulatory T cells, tumour immunity and immunotherapy (Review). Nat Rev Immunol 2006; 6: 295-307.
51. Simova J, Bubenik J, Bieblova J, Rosalia RA, Fric J, Reinis M. Depletion of T(reg) cells inhibits minimal residual disease after surgery of HPV16-associated tumours. Int J Oncol 2006; 29: 1567-1571.
52. Fecci PE, Sweeney AE, Grossi PM et al. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res 2006; 12: 4294-14230
53. Meloni F, Morosini M, Solari N et al. Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol 2006; 67: 1-12.
54. Bubenik J. Depletion of Treg cells augments the therapeutic effect of cancer vaccines. Folia Biol (Praha) 2006; 52: 202-204. (Pubitemid 46020164)